Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision animal health. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.

Zoetis Inc.

Revenue

Revenue %Chg

Revenue Common Size

Cost of Sales

Cost of Sales %Chg

Cost of Sales Common Size

Selling, General and Administrative Expenses

Selling, General and Administrative Expenses %Chg

Selling, General and Administrative Expenses Common Size

Research and Development Expenses

Research and Development Expenses %Chg

Research and Development Expenses Common Size

Amortization of Intangible Assets

Amortization of Intangible Assets %Chg

Amortization of Intangible Assets Common Size

Restructuring Charges and Certain Acquisition and Divestiture-Related Costs

Restructuring Charges and Certain Acquisition and Divestiture-Related Costs %Chg

Restructuring Charges and Certain Acquisition and Divestiture-Related Costs Common Size

Interest Expense, Net of Capitalized Interest

Interest Expense, Net of Capitalized Interest %Chg

Interest Expense, Net of Capitalized Interest Common Size

Other Deductions-Net

Other Deductions-Net %Chg

Other Deductions-Net Common Size

Income Before Provision for Taxes on Income

Income Before Provision for Taxes on Income %Chg

Income Before Provision for Taxes on Income Common Size

Provision for Taxes on Income

Provision for Taxes on Income %Chg

Provision for Taxes on Income Common Size

Net Income Before Allocation to Noncontrolling Interests

Net Income Before Allocation to Noncontrolling Interests %Chg

Net Income Before Allocation to Noncontrolling Interests Common Size

Net Income Attributable to Noncontrolling Interests

Net Income Attributable to Noncontrolling Interests %Chg

Net Income Attributable to Noncontrolling Interests Common Size

Net Income Attributable to Zoetis Inc.

Net Income Attributable to Zoetis Inc. %Chg

Net Income Attributable to Zoetis Inc. Common Size

Basic

Basic %Chg

Basic Common Size

Diluted

Diluted %Chg

Diluted Common Size

Dividends Declared per Common Share

Dividends Declared per Common Share %Chg

Dividends Declared per Common Share Common Size

Total Revenues

Total Revenues %Chg

Total Revenues Common Size

Gross Profit

Gross Profit %Chg

Gross Profit Common Size

Gross Profit Margin

Gross Profit Margin %Chg

Gross Profit Margin Common Size

Selling, General & Administrative Expenses

Selling, General & Administrative Expenses %Chg

Selling, General & Administrative Expenses Common Size

Depreciation & Amortization Expenses

Depreciation & Amortization Expenses %Chg

Depreciation & Amortization Expenses Common Size

Research & Development Expenses

Research & Development Expenses %Chg

Research & Development Expenses Common Size

Other Operating Expenses

Other Operating Expenses %Chg

Other Operating Expenses Common Size

Operating Profit

Operating Profit %Chg

Operating Profit Common Size

Operating Margin

Operating Margin %Chg

Operating Margin Common Size

Interest Expense

Interest Expense %Chg

Interest Expense Common Size

Non-Operating Income

Non-Operating Income %Chg

Non-Operating Income Common Size

Total Non-Operating Income

Total Non-Operating Income %Chg

Total Non-Operating Income Common Size

Income Before Provision for Income Taxes

Income Before Provision for Income Taxes %Chg

Income Before Provision for Income Taxes Common Size

Provision for Income Taxes

Provision for Income Taxes %Chg

Provision for Income Taxes Common Size

Consolidated Net Income

Consolidated Net Income %Chg

Consolidated Net Income Common Size

Net Income Attributable to Minority Interests and Other

Net Income Attributable to Minority Interests and Other %Chg

Net Income Attributable to Minority Interests and Other Common Size

Net Income Attributable to Common Shareholders

Net Income Attributable to Common Shareholders %Chg

Net Income Attributable to Common Shareholders Common Size

Basic EPS

Basic EPS %Chg

Basic EPS Common Size

Diluted EPS

Diluted EPS %Chg

Diluted EPS Common Size

Basic Weighted Average Shares Outstanding

EBIT

EBITDA

CapEx

Net Interest Income

Assets

Adjusted EBITDA

Adjusted Net Income

Net Revenue

Net Income

Average Assets

Adjusted EBIT

Adjusted Revenue

Adjusted EBT

Adjusted Funds From Operations

Income Statement	Jun '25	Dec '24	Jun '24	Dec '23	Jun '23	Dec '22
Total Revenues	4,680	4,705	4,551	4,364	4,180	4,042
Total Revenues %Chg	2.8%	7.8%	8.9%	8%	3.5%	2.1%
Revenue
Cost of Sales	1,271	1,408	1,311	1,366	1,195	1,260
Cost of Sales
Gross Profit	3,409	3,297	3,240	2,998	2,985	2,782
Gross Profit Margin	72.8%	70.1%	71.2%	68.7%	71.4%	68.8%
Selling, General & Administrative Expenses	1,180	1,190	1,128	1,090	1,061	1,015
Selling, General and Administrative Expenses
Depreciation & Amortization Expenses	65	69	72	75	74	72
Amortization of Intangible Assets
Research & Development Expenses	329	353	333	326	288	282
Research and Development Expenses
Other Operating Expenses	30	7	46	24	29	8
Restructuring Charges and Certain Acquisition and Divestiture-Related Costs
Operating Profit	1,805	1,678	1,661	1,483	1,533	1,405
Operating Margin	38.6%	35.7%	36.5%	34%	36.7%	34.8%
Interest Expense	-107	-108	-117	-118	-121	-115
Interest Expense, Net of Capitalized Interest
Non-Operating Income	14	36	-17	2	157	-31
Other Deductions-Net
Total Non-Operating Income	-93	-72	-134	-116	36	-146
Income Before Provision for Income Taxes	1,712	1,606	1,527	1,367	1,569	1,259
Income Before Provision for Taxes on Income
Provision for Income Taxes	363	333	304	248	348	271
Provision for Taxes on Income
Consolidated Net Income	1,349	1,273	1,223	1,119	1,221	988
Net Income Before Allocation to Noncontrolling Interests
Net Income Attributable to Minority Interests and Other	—	10	—	-2	-2	-2
Net Income Attributable to Noncontrolling Interests
Net Income Attributable to Common Shareholders	1,349	1,263	1,223	1,121	1,223	990
Net Income Attributable to Zoetis Inc.
Basic EPS	3	2.8	2.7	2.4	2.6	2.1
Diluted EPS	3	2.8	2.7	2.4	2.6	2.1
Basic Weighted Average Shares Outstanding	446.3	451.7	456.7	459.6	462.7	466.7
Total Shares Outstanding	443.9	448.7	453.8	458.4	460.8	463.8
Diluted Weighted Average Shares Outstanding	446.7	452.3	457.4	460.7	463.8	468
EBITDA	2,047	1,922	1,914	1,733	1,774	1,639
Effective Tax Rate	21.2%	20.7%	19.9%	18.1%	22.2%	21.5%